Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market.

The pharma company will in-license a small number of gene therapy products and offer research grants to advance them through pre-clinical development.

Laurus Labs will be responsible for launching these products in India and emerging markets.

The company will also establish a GMP facility at IIT Kanpur’s Techno Park facility.

Laurus Labs CEO Satyanarayana Chava stated: “This collaboration exhibits our commitment towards the cell and gene therapy (CGT) space.

“This partnership also provides a unique model for industry–academia collaboration and how we can leverage strengths from both sections for the benefit of patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company stated that the collaboration with IIT Kanpur allows it to strengthen its presence in the CGT space.

IITK’s department of biological sciences and bioengineering (BSBE) has been working on gene therapy for a number of years and has developed assets as well as technology for new adeno-associated virus (AAV) vectors.

IPs have been filed for these products, with additional patent applications planned to be filed soon.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.